JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (3): 391-395.doi: 10.3969/j.issn.1674-8115.2021.03.019

• Review • Previous Articles     Next Articles

Progress of cardioprotection effect of sodium-glucose cotransporter 2 inhibitor on patients with type 2 diabetes

Min SUN(), Dong-ying ZHANG()   

  1. Department of Cardiovascular, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
  • Received:2019-12-23 Online:2021-03-28 Published:2021-04-06
  • Contact: Dong-ying ZHANG;


As a novel anti-diabetes drug, sodium-glucose cotransporter 2 inhibitor (SGLT2i) can decrease the all-cause mortality, the risk of major adverse cardiac event (MACE) and rate of heart failure hospitalization in patients with type 2 diabetes. Studies found that besides the function of glycemic control, SGLT2i could reduce the preload and afterload of heart, improve the hemodynamics, attenuate myocardial fibrosis and rejuvenate myocardial energetics. In this paper, clinical trials about SGLT2i in recent years and the mechanisms are reviewed to discuss the progress of the cardioprotection effect of SGLT2i on patients with type 2 diabetes.

Key words: sodium-glucose cotransporter 2 inhibitor, type 2 diabetes, cardiovascular disease, empagliflozin, canagliflozin, dapagliflozin

CLC Number: